Methotrexate

Generic Name
Methotrexate
Brand Names
Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
Drug Type
Small Molecule
Chemical Formula
C20H22N8O5
CAS Number
59-05-2
Unique Ingredient Identifier
YL5FZ2Y5U1
Background

Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.

Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments.

Methotrexate was granted FDA approval on 7 December 1953.

Indication

Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.

Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma. It is also used in the maintenance of acute lymphocytic leukemia. Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
Associated Therapies
Medically induced abortion

Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia

First Posted Date
2003-01-27
Last Posted Date
2014-02-20
Lead Sponsor
Children's Oncology Group
Target Recruit Count
6
Registration Number
NCT00022126
Locations
🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Emory University Hospital - Atlanta, Atlanta, Georgia, United States

🇺🇸

Loma Linda University Medical Center, Loma Linda, California, United States

and more 48 locations

Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia

First Posted Date
2003-01-27
Last Posted Date
2018-05-15
Lead Sponsor
Gynecologic Oncology Group
Target Recruit Count
240
Registration Number
NCT00003702
Locations
🇺🇸

Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Phase 2
Completed
Conditions
First Posted Date
2003-01-27
Last Posted Date
2013-12-19
Lead Sponsor
Medical Research Council
Target Recruit Count
120
Registration Number
NCT00040690
Locations
🇬🇧

Medical Research Council Clinical Trials Unit, London, England, United Kingdom

Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Phase 2
Completed
Conditions
First Posted Date
2003-01-27
Last Posted Date
2013-06-25
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
30
Registration Number
NCT00002598
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer

Phase 3
Completed
Conditions
First Posted Date
2003-01-27
Last Posted Date
2013-12-19
Lead Sponsor
University Hospital Birmingham
Target Recruit Count
2250
Registration Number
NCT00003893
Locations
🇬🇧

Queen Elizabeth Hospital at University of Birmingham, Birmingham, England, United Kingdom

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Phase 2
Completed
Conditions
First Posted Date
2003-01-27
Last Posted Date
2012-06-06
Lead Sponsor
Northwestern University
Registration Number
NCT00004231
Locations
🇺🇸

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer

Phase 3
Completed
Conditions
First Posted Date
2003-01-27
Last Posted Date
2013-12-19
Lead Sponsor
University Hospital Birmingham
Target Recruit Count
2000
Registration Number
NCT00003577
Locations
🇬🇧

University of Cambridge, Cambridge, England, United Kingdom

Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer

First Posted Date
2003-01-27
Last Posted Date
2024-03-08
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
90
Registration Number
NCT00036868
Locations
🇷🇸

Institute of Oncology and Radiology of Serbia, Belgrade, Serbia

🇫🇷

Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France

🇪🇬

National Cancer Institute of Egypt, Cairo, Egypt

and more 10 locations

Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

Phase 3
Conditions
First Posted Date
2003-01-27
Last Posted Date
2013-12-04
Lead Sponsor
Medical Research Council
Target Recruit Count
1800
Registration Number
NCT00003437
Locations
🇬🇧

Oxford Radcliffe Hospital, Oxford, England, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath